Brief: Poxel And Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results For Imeglimin Phase 3 Trial (TIMES 3) In Japan

Poxel SA

25/06/2019 07:20

June 25 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE SECOND
POSITIVE
TOP-LINE RESULTS FOR IMEGLIMIN PHASE 3 TRIAL (TIMES 3) IN JAPAN
FOR THE TREATMENT OF TYPE 2 DIABETES
    * POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE SECOND
POSITIVE
TOP-LINE RESULTS FOR IMEGLIMIN PHASE 3 TRIAL (TIMES 3) IN JAPAN
FOR THE TREATMENT OF TYPE 2 DIABETES
    * PHASE 3 RESULTS FROM TIMES 2 AND 36-WEEK OPEN-LABEL
EXTENSION
PART OF TIMES 3 ARE ANTICIPATED AROUND END OF 2019
    * IMEGLIMIN JAPANESE NEW DRUG APPLICATION (JNDA) TARGETED
FOR 2020
    * IMEGLIMIN IN COMBINATION WITH INSULIN PHASE 3 TIMES 3
16-WEEK,
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PART OF TRIAL MET
ITS PRIMARY ENDPOINT

Source text for Eikon:  ID:nBwBF09Xa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))